Protein Drugs

By rational protein design and working with ProDa, we have developed a protein agent called ProAngio that targets integrin alphavbeta3 at a novel site in collaboration with Dr. Zhiren Liu. The protein agent induces integrin alphavbeta3 mediated cell apoptosis by a mechanism that differs from anoikis, providing unique advantages in developing therapeutics targeting integrin alphavbeta3. The designed protein is very potent in treatment of a number of human diseases, such as cancers and liver fibrosis/cirrhosis. This protein agent is moving into clinical studies as a multi-application protein drug candidate.


  • • Ravi Chakra Turaga, Lu Yin, Jenny J. Yang, Hsiauwei Lee, Ivaylo N. Ivanov, Chunli Yan,Hua Yang, Hans E. Grossniklaus, Siming Wang, Cheng Ma, Li Sun, and Zhi-Ren Liu Development of Anti-angiogenic Agents Targeting Integrins alphavbeta3 by Rational Protein Design Nature Communication Nature Communication 2016 May 31;7:11675. doi: 10.1038/ncomms11675.


  • Zhi-Ren Liu, Jenny Yang, and Lu Yin, Novel anti-angiogenesis proteins for cancer therapy PCT/US11/043907 (2011); Nov 3, 2015, Grant